Persisting Gaps in Optimal Care of Stage III Non-small Cell Lung Cancer: An Australian Patterns of Care Analysis

5Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

BACKGROUND: Wide variation exists globally in the treatment and outcomes of stage III patients with non-small cell lung cancer (NSCLC). We conducted an up-to-date patterns of care analysis in the state of Victoria, Australia, with a particular focus on the proportion of patients receiving treatment with radical intent, treatment trends over time, and survival. MATERIALS AND METHODS: Stage III patients with NSCLC were identified in the Victorian Lung Cancer Registry and categorized by treatment received and treatment intent. Logistic regression was used to explore factors predictive of receipt of radical treatment and the treatment trends over time. Cox regression was used to explore variables associated with overall survival (OS). Covariates evaluated included age, sex, ECOG performance status, smoking status, year of diagnosis, Australian born, Aboriginal or Torres Strait Islander status, socioeconomic status, rurality, public/private status of notifying institution, and multidisciplinary meeting discussion. RESULTS: A total of 1396 patients were diagnosed between 2012 and 2019 and received treatment with radical intent 67%, palliative intent 23%, unknown intent 5% and no treatment 5%. Radical intent treatment was less likely if patients were >75 years, ECOG ≥1, had T3-4 or N3 disease or resided rurally. Surgery use decreased over time, while concurrent chemoradiotherapy and immunotherapy use increased. Median OS was 38.0, 11.1, and 4.4 months following radical treatment, palliative treatment or no treatment, respectively. CONCLUSION: Almost a third of stage III patients with NSCLC still do not receive radical treatment. Strategies to facilitate radical treatment and better support decision making between increasing multimodality options are required.

References Powered by Scopus

Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer

3572Citations
N/AReaders
Get full text

Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC

2274Citations
N/AReaders
Get full text

Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE collaborative group

2232Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Chronic respiratory disease in Indigenous peoples: a framework to address inequity and strengthen respiratory health and health care globally

8Citations
N/AReaders
Get full text

Disease prognosis and therapeutic strategies in patients with advanced non-small cell lung cancer (NSCLC): a 6-year epidemiological study between 2015–2021

3Citations
N/AReaders
Get full text

Quality Indicators for Non-Small Cell Lung Cancer in Queensland, Australia, 2012–2021

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Woodford, K., Koo, K., Reynolds, J., Stirling, R. G., Harden, S. V., Brand, M., & Senthi, S. (2023). Persisting Gaps in Optimal Care of Stage III Non-small Cell Lung Cancer: An Australian Patterns of Care Analysis. The Oncologist, 28(2), e92–e102. https://doi.org/10.1093/oncolo/oyac246

Readers over time

‘22‘23‘24‘2502468

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 1

100%

Readers' Discipline

Tooltip

Medicine and Dentistry 2

33%

Biochemistry, Genetics and Molecular Bi... 2

33%

Nursing and Health Professions 2

33%

Save time finding and organizing research with Mendeley

Sign up for free
0